Related Experiment Video

Updated: Sep 4, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Tivozanib for the treatment of advanced renal cell carcinoma

Jonathan Chatzkel1, Brian Ramnaraign1, Guru Sonpavde2

  • 1Division of Hematology and Oncology, University of Florida, Gainesville, FL, USA.

Expert Opinion on Pharmacotherapy
|July 18, 2022
PubMed
Abstract

Insights

Tivozanib, a vascular endothelial growth factor receptor inhibitor, is approved for advanced renal cell carcinoma (RCC). It offers a favorable safety profile for pretreated patients and may be combined with other therapies in ongoing studies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) represents 2.4% of cancers, with advanced stages having a poor prognosis.
  • Clear cell kidney cancer is the most common subtype of RCC.
  • Despite advances, 5-year survival for advanced RCC is low (13.9% in the US).

Purpose of the Study:

  • To review the development and role of tivozanib in treating advanced renal cell carcinoma (RCC).
  • To compare tivozanib with other vascular endothelial growth factor (VEGF) receptor inhibitors.
  • To discuss tivozanib's place in the current treatment landscape and ongoing research.

Main Methods:

  • Review of tivozanib's development.
  • Comparative analysis of tivozanib against other VEGF receptor inhibitors.
  • Evaluation of tivozanib's clinical utility and ongoing studies.

Main Results:

  • Tivozanib is a novel inhibitor of VEGFR-1, -2, and -3.
  • Tivozanib has an excellent safety profile and demonstrated clinical benefit in pretreated patients.
  • Tivozanib is approved by the US FDA for relapsed/recurrent advanced RCC after two or more systemic therapies.

Conclusions:

  • Tivozanib is expected to be widely used in later-line treatment settings for advanced RCC.
  • The TINIVO-2 study is evaluating tivozanib plus nivolumab in patients progressing on immune checkpoint inhibitors.
  • Tivozanib represents a significant therapeutic option for advanced renal cell carcinoma.
Keywords:
TivozanibVEGF inhibitoradvancedkidney cancerrecurrentrenal cell carcinoma

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

585

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
148
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
248
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652